These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32600913)

  • 1. Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230.
    Scaria PV; Chen BB; Rowe CG; Alani N; Muratova OV; Barnafo EK; Lambert LE; Zaidi IU; Lees A; Rausch KM; Narum DL; Duffy PE
    Vaccine; 2020 Jul; 38(34):5480-5489. PubMed ID: 32600913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.
    Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
    Talaat KR; Ellis RD; Hurd J; Hentrich A; Gabriel E; Hynes NA; Rausch KM; Zhu D; Muratova O; Herrera R; Anderson C; Jones D; Aebig J; Brockley S; MacDonald NJ; Wang X; Fay MP; Healy SA; Durbin AP; Narum DL; Wu Y; Duffy PE
    PLoS One; 2016; 11(10):e0163144. PubMed ID: 27749907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cell clonal expansion and mutation in the immunoglobulin heavy chain variable domain in response to Pfs230 and Pfs25 malaria vaccines.
    Coelho CH; Galson JD; Trück J; Duffy PE
    Int J Parasitol; 2022 Oct; 52(11):707-710. PubMed ID: 34896314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230.
    Scaria PV; Rowe CG; Chen BB; Muratova OV; Fischer ER; Barnafo EK; Anderson CF; Zaidi IU; Lambert LE; Lucas BJ; Nahas DD; Narum DL; Duffy PE
    NPJ Vaccines; 2019; 4():24. PubMed ID: 31312527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice.
    Coelho CH; Gazzinelli-Guimaraes PH; Howard J; Barnafo E; Alani NAH; Muratova O; McCormack A; Kelnhofer E; Urban JF; Narum DL; Anderson C; Langhorne J; Nutman TB; Duffy PE
    Vaccine; 2019 Feb; 37(8):1038-1045. PubMed ID: 30685251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination.
    Parzych EM; Miura K; Long CA; Burns JM
    PLoS One; 2020; 15(4):e0232355. PubMed ID: 32348377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose.
    Huang WC; Deng B; Mabrouk MT; Seffouh A; Ortega J; Long C; Miura K; Wu Y; Lovell JF
    Malar J; 2020 Aug; 19(1):309. PubMed ID: 32859199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.
    MacDonald NJ; Nguyen V; Shimp R; Reiter K; Herrera R; Burkhardt M; Muratova O; Kumar K; Aebig J; Rausch K; Lambert L; Dawson N; Sattabongkot J; Ambroggio X; Duffy PE; Wu Y; Narum DL
    J Biol Chem; 2016 Sep; 291(38):19913-22. PubMed ID: 27432885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of malaria transmission-blocking vaccine candidate, y230.CA14 following crosslinking in the presence of tetanus toxoid.
    Vincent AA; Fanning S; Caira FC; Williamson KC
    Parasite Immunol; 1999 Nov; 21(11):573-81. PubMed ID: 10583858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates.
    Qian F; Wu Y; Muratova O; Zhou H; Dobrescu G; Duggan P; Lynn L; Song G; Zhang Y; Reiter K; MacDonald N; Narum DL; Long CA; Miller LH; Saul A; Mullen GE
    Vaccine; 2007 May; 25(20):3923-33. PubMed ID: 17428587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.
    Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P
    Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum.
    Miura K; Deng B; Wu Y; Zhou L; Pham TP; Diouf A; Wu CK; Lee SM; Plieskatt JL; Morin MJ; Long CA
    Vaccine; 2019 Apr; 37(15):2073-2078. PubMed ID: 30850239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding.
    Kumar R; Angov E; Kumar N
    Infect Immun; 2014 Apr; 82(4):1453-9. PubMed ID: 24421036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.
    Shimp RL; Rowe C; Reiter K; Chen B; Nguyen V; Aebig J; Rausch KM; Kumar K; Wu Y; Jin AJ; Jones DS; Narum DL
    Vaccine; 2013 Jun; 31(28):2954-62. PubMed ID: 23623858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of domains within Pfs230 that elicit transmission blocking antibody responses.
    Tachibana M; Miura K; Takashima E; Morita M; Nagaoka H; Zhou L; Long CA; Richter King C; Torii M; Tsuboi T; Ishino T
    Vaccine; 2019 Mar; 37(13):1799-1806. PubMed ID: 30824357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
    Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®.
    Zhu D; Wu Y; McClellan H; Dai W; Rausch K; Jones D; Aebig J; Barnafo E; Butler B; Lambert L; Narum DL; Duffy PE
    Vaccine; 2017 May; 35(24):3232-3238. PubMed ID: 28479180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
    Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
    Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant
    Parzych EM; Miura K; Ramanathan A; Long CA; Burns JM
    Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.